You are here: Industry Insights > Merck

News List

FDA Approves TEPMETKO? as the First and Only Once-daily Oral MET Inhibitor for Patients with Metastatic NSCLC with METex14 Skipping Alterations prnasia
February 04, 2021
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has approved TEPMETKO? (tepotinib) following Priority Review for the treatment of adult patients with metastatic non-small cell lung cancer ...
500+ Sites Join Inato’s Industry Marketplace contractpharma
January 27, 2021
?Inato, a global industry marketplace that matches research sites to the right clinical trial protocols, has announced that over 500 sites across more than 30 countries are participating in its Marketplace.
Merck Discontinues Development of SARS-CoV-2/COVID-19 Vaccine Candidates americanpharmaceuticalreview
January 26, 2021
Merck announced the company is discontinuing development of its SARS-CoV-2/COVID-19 vaccine candidates, V590 and V591, and plans to focus its SARS-CoV-2/COVID-19 research strategy and production capabilities on advancing two therapeutic candidates ...
European Commission Approves BAVENCIO? (avelumab) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma prnasia
January 25, 2021
Merck and Pfizer Inc. today announced that the European Commission (EC) has approved BAVENCIO? (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are ...
Merck Announces Update on the INTR@PID Clinical Program Including Lung 037 Study prnasia
January 21, 2021
Merck, a leading science and technology company, announced an update on the Phase III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program for the potential first-in-class investigational bifunctional immunotherapy bintrafusp alfa ...
FDA accepts priority review of Merck’s pneumococcal vaccine pharmaceutical-technology
January 14, 2021
The US Food and Drug Administration (FDA) has accepted priority review of the Biologics License Application (BLA) of Merck’s investigational 15-valent pneumococcal conjugate vaccine candidate, V114, for preventing invasive pneumococcal disease in adults.
Merck acquires Germany-based CDMO, AmpTec expresspharma
January 08, 2021
The acquisition to expand Merck’s lipid manufacturing expertise and mRNA capabilities for vaccines, treatments and diagnostics.
Merck announces supply agreement with US for initial doses of investigational biological therapy to treat Covid-19 pharmaceutical-business-review
December 29, 2020
Merck acquired MK-7110 through the acquisition of OncoImmune, a privately held, clinical-stage biopharmaceutical company.
Merck reports positive results for Keytruda, Lenvima combo in phase 3 KEYNOTE-775/Study 309 trial pharmaceutical-business-review
December 21, 2020
Merck and Eisai announced that the pivotal Phase 3 KEYNOTE-775/Study 309 trial evaluating the investigational use of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai ..
EU to review Merck's targeted lung cancer drug pharmatimes
November 30, 2020
European regulators will review Merck's tepotinib for a specific type of lung cancer, having validated the drug's marketing application.